Athenex, Inc. (ATNX)
| Market Cap | 413.54M |
| Revenue (ttm) | 138.48M |
| Net Income (ttm) | -151.80M |
| Shares Out | 93.43M |
| EPS (ttm) | -1.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $3.66 |
| Previous Close | $3.75 |
| Change ($) | -0.09 |
| Change (%) | -2.40% |
| Day's Open | 3.77 |
| Day's Range | 3.65 - 3.82 |
| Day's Volume | 1,267,841 |
| 52-Week Range | 3.65 - 15.24 |
Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada Athenex expands its international commercial partnerships for tirbanibulin in Australia, N...
BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...
Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.
BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...
Wall Street recommends buying shares of Athenex Inc. ( ATNX , Financial) and Bellerophon Therapeutics Inc. ( BLPH , Financial). This sounds quite surprising as these two equities have performed poorly o...
Athenex Inc (NASDAQ: ATNX) held a Type A meeting with the FDA during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter (CRL) regarding application for oral pa...
BUFFALO, N.Y., July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...
SAN DIEGO & BUFFALO, N.Y.--(BUSINESS WIRE)---- $ATNX #ATNX--Shareholder rights law firm Robbins LLP is investigating Athenex, Inc. (NASDAQ: ATNX) to determine whether certain Athenex officers and direct...
BUFFALO, N.Y., June 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...
European Commission Decision Anticipated by July 2021 European Commission Decision Anticipated by July 2021
BUFFALO, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the...
Athenex (ATNX) delivered earnings and revenue surprises of 27.03% and 110.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Athenex (NASDAQ:ATNX) moved higher by 2.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 12.50% over the past year to ($0.27), whi...
Plan to Request Type A Meeting with the FDA for Oral Paclitaxel by the End of May
A blockbuster acquisition could help the biotech "convert cancer into a chronic disease."
Athenex Inc (NASDAQ: ATNX) shares have risen during premarket trading in reaction to acquiring Kuur Therapeutics Inc, a portfolio company of IP Group plc, for $70 million upfront. Additionally, Kuur sha...
BUFFALO, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...
New York, New York--(Newsfile Corp. - May 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Athene...
Los Angeles, California--(Newsfile Corp. - May 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athenex"...
NEW YORK, May 3, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action ...
New York, New York--(Newsfile Corp. - May 2, 2021) - WHY:. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 ...
New York, New York--(Newsfile Corp. - April 30, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Athenex, Inc.. (NASDAQ: ATNX)Sha...
New York, New York--(Newsfile Corp. - April 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Athenex, Inc. (NASD...
New York, New York--(Newsfile Corp. - April 30, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Athenex, Inc. (NASDAQ: ATNX) alleging that ...
Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athen...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company") (NASD...
San Francisco, California--(Newsfile Corp. - April 29, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now.Class Period: Aug. 7, 2019 - F...
New York, New York--(Newsfile Corp. - April 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 201...
Los Angeles, California--(Newsfile Corp. - April 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athen...
LOS ANGELES--(BUSINESS WIRE)---- $ATNX #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)
New York, New York--(Newsfile Corp. - April 29, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company"...
New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) and certain o...
Boston, Massachusetts--(Newsfile Corp. - April 28, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Athenex, Inc. (NASDAQ: ATNX). The c...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company") (NASD...
Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athen...
San Francisco, California--(Newsfile Corp. - April 27, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now.Class Period: Aug. 7, 2019 - F...
BUFFALO, N.Y., April 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...
NEW YORK--(BUSINESS WIRE)-- #ATNX--Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Athenex, Inc. (ATNX) and May 3 Deadline
New York, New York--(Newsfile Corp. - April 24, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 201...
NEW YORK, April 23, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February ...
Boston, Massachusetts--(Newsfile Corp. - April 22, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Athenex, Inc. (NASDAQ: ATNX). The c...
Los Angeles, California--(Newsfile Corp. - April 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athen...
Boston, Massachusetts--(Newsfile Corp. - April 20, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit o...
San Francisco, California--(Newsfile Corp. - April 20, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 - ...
Boston, Massachusetts--(Newsfile Corp. - April 20, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Athenex, Inc. (NASDAQ: ATNX). The c...
LOS ANGELES, April 16, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athenex" or "the Comp...
San Francisco, California--(Newsfile Corp. - April 14, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 - ...
New York, New York--(Newsfile Corp. - April 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 201...
San Francisco, California--(Newsfile Corp. - April 8, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 - ...
NEW YORK--(BUSINESS WIRE)-- #ATNX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 20...
About ATNX
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer d... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jun 14, 2017 |
| CEO Johnson Lau | Employees 593 |
| Stock Exchange NASDAQ | Ticker Symbol ATNX |
Financial Performance
In 2020, Athenex's revenue was $144.39 million, an increase of 42.64% compared to the previous year's $101.23 million. Losses were -$146.18 million, 18.1% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for Athenex stock is "Buy." The 12-month stock price forecast is 9.75, which is an increase of 166.39% from the latest price.